Press Releases - Selux Diagnostics

In the News

Selux Receives FDA Clearance on Their Gram-Negative Panel

June 16, 2023

FDA Clears ‘Selux NGP System’ for Rapid Antibiotic Susceptibility Testing

January 19, 2023

Dr. James S. Lewis II, Antibiotic Susceptibility Test Expert, Joins as Chair of Selux Diagnostics’ Clinical Advisory Board

October 18, 2022

Selux Diagnostics Announces Additional $50 Million in Series C Funding

February 28, 2022

Selux Diagnostics Announces Appointment of John Wilson as Chief Commercial Officer

November 16, 2021

Selux Diagnostics Awarded $2.8 Million Grant from NIH for Commercialization of its NGP Platform

October 19, 2021

Selux Diagnostics Earns FDA Breakthrough Device Designation for Next Generation ‘Phenotyping’ (NGP) Platform for Positive Blood Culture and Sterile Body Fluid Samples

September 28, 2021

Selux Diagnostics Receives Additional $14.6 Million in BARDA Funding After Successfully Completing First Clinical Trial

June 9, 2021

Selux Diagnostics Receives $9.6 Million in Additional Funding, Speeding Development of Breakthrough Rapid AST Platform

April 27, 2020

ECCMID 2020 Alert: Selux Diagnostics Hosting Integrated Symposium at 30th European Congress of Clinical Microbiology & Infectious Diseases

February 18, 2020

Selux Diagnostics Beats Key Contract Milestone, Receives $11.4M in Additional Funding

October 2, 2019

Selux Diagnostics Selected to lead IDWeek 2019 Panel Presentation, Poster Session

September 10, 2019

Selux Diagnostics Announces Selection of Three Abstracts for Poster Sessions at ASM Microbe Conference

June 10, 2019